-
Posted by
Two Blokes Jul 9 -
Filed in
Stock
-
4 views
Facing a looming patent cliff on its blockbuster cancer drug Keytruda, Merck & Co Inc (NYSE:MRK, ETR:6MK) is putting the finishing touches to a $10 billion deal to acquire Verona Pharma, a specialist in lung disease therapies, the Financial Times reported. The planned purchase price of $107 per American Depositary Share represents a 35% premium to Verona's most recent Nasdaq close.
